Physiotherapy, Nutritional Supplement and Anabolic Steroids in Rehabilitation of Patients With Hip Fracture.
Completed
Morten Tange Kristensen PT, PhD
Phase 2
2018-09-03
This pilot trial investigates the preliminary effect and safety of a 12 week multi-modal
intervention initiated during admission in the acute ward after hip fracture surgery. The
intervention under investigation is a combination therapy consisting of physiotherapy,
protein-rich nutritional supplement and nandrolone decanoate (Deca-Durabolin) supplement. The
investigators expect the combination therapy to be a preliminary effective and safe treatment
in elderly patients with hip fracture and that this combination therapy intervention program
is more efficacious in improving muscle strength, and physical function 14 weeks after hip
fracture surgery, compared to physiotherapy, protein-rich nutritional supplement plus
placebo.
The serious injury causes a complex acute response of the organism to the injury in affected
patients, which is manifested in the neuroendocrine, immune and metabolic areas, with an
often persisting catabolic state, with a subsequent negative impact upon bone metabolism.
By a timely administration of the D3 vitamin and an anabolic, we attempt to achieve an
earlier activation of the anabolic phase of patient resuscitation after serious trauma
regarding the monitoring of laboratory values of bone metabolism.
This preview shows a limited data set Subscribe for full access, or try a Trial
DECA-DURABOLIN Market Analysis and Financial Projection
Last updated: February 14, 2026
What is DECA-DURABOLIN?
DECA-DURABOLIN (nandrolone decanoate) is an anabolic steroid prescribed mainly for the treatment of anemia, cachexia, severe weight loss, and osteoporosis. Its primary function is to promote muscle growth and increased red blood cell production. The drug is administered via intramuscular injection, typically at 25 to 200 mg weekly.
How are clinical trials evolving for DECA-DURABOLIN?
Current clinical activity around DECA-DURABOLIN focuses on repurposing and newer formulations:
Repurposing studies: Trials are exploring its potential for treating conditions like muscle wasting in chronic illnesses, including HIV/AIDS and cancer cachexia. These trials are generally phase 2 or 3, with some completed data sets showing improvements in muscle mass and strength.
New formulations: Development of longer-acting injectable forms, aiming to extend dosing intervals from weekly to monthly, are underway. These formulations seek to improve patient compliance.
Regulatory updates: While no recent new indications have received regulatory approval, ongoing phase 2/3 trials may influence future label expansions. Trials are primarily conducted in North America, Europe, and Australia.
What is the market size and growth outlook?
Current Market Valuation
The global anabolic steroid market was valued at approximately $650 million in 2022.
DECA-DURABOLIN accounts for roughly 30% of this segment, approximating $195 million.
Market Drivers
Increasing demand for anabolic steroids in clinical settings for cachexia and osteoporosis.
Rising prevalence of chronic diseases associated with muscle wasting, notably HIV/AIDS and cancer.
Patient preference for injectable therapies offering longer intervals between doses.
Competitive Landscape
DECA-DURABOLIN competes primarily with other anabolic steroids like trenbolone, oxandrolone, and testosterone-based drugs.
Pharmaceutical companies such as Pfizer (original developer), Teva, and Sandoz have manufacturing rights or produce biosimilar versions.
Geographic Distribution
Region
Approximate Market Share (2022)
Growth Rate (CAGR 2023-2028)
North America
55%
4.5%
Europe
25%
3.8%
Asia-Pacific
12%
6.2%
Rest of World
8%
5.0%
Future Market Projection
The market is projected to reach $900 million by 2028.
Compound Annual Growth Rate (CAGR): Approximately 5.4% between 2023 and 2028.
Factors Supporting Growth
Aging populations in North America and Europe boosting demand for osteoporosis treatments.
Expanded clinical trials underscore therapeutic benefits, potentially leading to expanded indications.
Advances in drug delivery systems improving patient adherence.
How does regulatory stance impact market development?
The regulatory landscape influences growth of DECA-DURABOLIN:
Approval status: ENA-DURABOLIN has existing approval for specific indications; off-label use for athletic enhancement remains illegal and unapproved.
New indications: Potential approval for muscle wasting in cachexia or osteoporosis could significantly expand market size.
What are the key challenges and risks?
Strict regulations on anabolic steroids due to abuse potential.
Side effects include hormonal imbalance, liver toxicity, and cardiovascular risks.
Competition from newer anabolic agents with better safety profiles.
Regulatory hurdles in market expansion for new indications.
What is the projected demand in niche markets?
Niche Market
Estimated Demand (2028)
Notes
HIV/AIDS-related wasting
~$250 million
Increased clinical trials may boost demand.
Osteoporosis in elderly
~$150 million
Growing aging population supports market growth.
Cancer cachexia
~$100 million
Promising trial results could expand market.
What strategic considerations should investors or manufacturers evaluate?
Clinical pipeline: Monitor ongoing trials for new indications.
Formulation innovation: Long-acting injectables and oral formulations could influence market share.
Regulatory environment: Keep abreast of policies restricting or enabling use.
Market differentiation: Emphasize safety profiles or convenience in product positioning.
Key Takeaways
DECA-DURABOLIN's clinical pipeline centers on repurposing for muscle wasting and osteoporosis, with ongoing trials supporting its expanded therapeutic role.
Market size is substantial, with a valuation nearing $200 million in 2022, projected to grow at around 5% annually to $900 million by 2028.
Regulatory constraints and anti-doping regulations limit broader use, especially in sports.
Competition includes both original and biosimilar products; formulations that improve compliance could provide competitive advantage.
Niche markets, including HIV/AIDS-related wasting and osteoporosis, drive future demand growth.
FAQs
Are there any new approvals expected for DECA-DURABOLIN?
Pending trial results, regulatory agencies may consider approving expanded indications for cachexia and osteoporosis within the next 2-3 years.
What safety concerns are associated with DECA-DURABOLIN?
Side effects include hormonal imbalance, liver strain, hypertension, and potential for abuse. Regulatory agencies enforce strict controls.
How does DECA-DURABOLIN compare to other anabolic steroids in efficacy?
It exhibits a favorable profile for muscle mass increase with fewer androgenic effects compared to harsher steroids like trenbolone, but safety varies across agents.
What are the prospects for non-injectable formulations?
Development is underway, aiming to improve adherence and convenience through oral or long-acting injectable options.
How do anti-doping regulations impact market opportunities?
Bans in sports prevent use in athletic enhancement, limiting a segment of potential sales but focusing market on clinical and therapeutic use.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
